source
- Alzheon seeks up to $500M in new financing after Phase 3 setback for Alzheimer’s drugAlzheon, a biotech based in Framingham, Massachusetts, has been pursuing an Alzheimer’s therapy for more than a decade. Its lead candidate recently failed to achieve the primary goals in a Phase 3…
- Pro-vaccine advocates urged to add celebration to messaging after new safety data confirms flu, Covid-19 and RSV shotsPublic‑health communications consultant Adam Zimmerman argues that vaccine advocacy has lost its festive spirit and needs more fun to engage the public. He recalls the 1955 "vaccine party" when th…